Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Total Assets of $1.02 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -44.2% in Total Assets from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $3.25 million | Q1 2012: $2.25 million | Q3 2012: $5.72 million | Q1 2013: $4.75 million | Q2 2013: $3.79 million | Q3 2013: $6.21 million | Q1 2014: $4.19 million | Q2 2014: $12.52 million | Q3 2014: $11.40 million | Q1 2015: $22.39 million | Q2 2015: $20.36 million | Q3 2015: $18.36 million | Q1 2016: $13.81 million | Q2 2016: $13.15 million | Q3 2016: $11.72 million | Q1 2017: $9.03 million | Q2 2017: $8.00 million | Q3 2017: $11.34 million | Q1 2018: $9.41 million | Q2 2018: $21.02 million | Q3 2018: $13.77 million | Q1 2019: $11.85 million | Q2 2019: $8.86 million | Q3 2019: $7.81 million | Q1 2020: $18.07 million | Q2 2020: $19.22 million | Q3 2020: $32.69 million | Q1 2021: $48.57 million | Q2 2021: $42.24 million | Q3 2021: $34.54 million | Q1 2022: $25.79 million | Q2 2022: $18.96 million | Q3 2022: $13.25 million | Q1 2023: $7.87 million | Q2 2023: $5.75 million | Q3 2023: $5.68 million | Q1 2024: $3.35 million | Q2 2024: $5.68 million | Q3 2024: $2.03 million | Q1 2025: $3.57 million | Q2 2025: $2.57 million | Q3 2025: $1.38 million.
- Over the full 16 years of available data (2010 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Total Assets has declined by 6.2%.
- Historical annual values: Fiscal year 2025: $1.02 million | Fiscal year 2024: $1.83 million | Fiscal year 2023: $4.21 million | Fiscal year 2022: $8.45 million | Fiscal year 2021: $29.28 million | Fiscal year 2020: $51.26 million | Fiscal year 2019: $6.53 million | Fiscal year 2018: $11.23 million | Fiscal year 2017: $11.42 million | Fiscal year 2016: $10.77 million | Fiscal year 2015: $17.08 million | Fiscal year 2014: $9.91 million | Fiscal year 2013: $4.73 million | Fiscal year 2012: $5.14 million | Fiscal year 2011: $2.74 million | Fiscal year 2010: $1.09 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: